Maravai LifeSciences Holdings, Inc. - Class A common stock (MRVI)
5.1350
+0.0850 (1.68%)
Maravai Lifesciences Holdings Inc is a biotechnology company that specializes in providing critical products and services for life sciences research and drug development
The company focuses on the supply of essential reagents and tools that support various applications, including mRNA production, immunotherapy, and cell and gene therapies. By offering a range of high-quality solutions, Maravai enables researchers and pharmaceutical companies to accelerate scientific discovery and the development of innovative therapies, playing a vital role in advancing public health and medicine.
U.S. stocks were lower, with the Dow Jones index falling over 200 points on Tuesday. Shares of BlackBerry Limited (NYSEBB) rose sharply during Tuesday’s session.
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling around 0.2% on Friday. The Dow traded up 0.23% to 39,158.52 while the NASDAQ fell 0.19% to 16,011.27. The S&P 500 also rose, gaining, 0.11% to 5,092.83. Leading and Lagging Sectors
Maravai LifeSciences impresses with Q4 2023 revenue of $74.1 million, surpassing estimates. CEO Trey Martin highlights strong execution, cost reductions, and a 28% adjusted EBITDA margin. 2024 revenue guidance of $265-$285 million exceeds expectations.
U.S. stocks traded mostly higher midway through trading, with the Dow Jones index jumping more than 100 points on Friday. The Dow traded up 0.36% to 39,209.32 while the NASDAQ rose 0.01% to 16,042.80. The S&P 500 also rose, gaining, 0.18% to 5,096.40. Leading and Lagging Sectors
